• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[经免疫治疗获得实验性动脉粥样硬化抗性的家兔的胆固醇代谢]

[Cholesterol metabolism in rabbits with resistance to experimental atherosclerosis acquired by immunological treatment].

作者信息

Klimov A N, Dokusova O K, Petrova-Maslakova L G, Loviagina T N, Nagornev V A

出版信息

Vopr Med Khim. 1977 Nov-Dec(6):803-7.

PMID:202092
Abstract

Development of resistance to experimental atherosclerosis due to immunization of newborn rabbits with homologous fraction of beta- and pre-beta-lipoproteins was accompanied by increased oxidation of cholesterol to biliary acids and by accelerated excretion of cholesterol. The phenomenon appears to be caused by two mechanisms: 1 (cholesterol, occurring in the fraction of free lipoproteins "unblocked" by the antibody (immunzied animals), is more readily oxidized to biliary acids in liver tissue than cholesterol, occurring in the autoimmune complex "lipoprotein-antibody" (non-immunized animals)); 2) the enzymes and biological systems, responsible for elimination of cholesterol from an organism (oxidation to biliary acids, excretion with bile), are activated after immunization of the newborn animals by the lipoprotein fraction endriched with cholesterol.

摘要

新生兔用β-脂蛋白和前β-脂蛋白的同源部分进行免疫后,对实验性动脉粥样硬化产生抗性的过程中,伴随着胆固醇氧化为胆汁酸的增加以及胆固醇排泄的加速。该现象似乎由两种机制引起:1)(在抗体“解除阻滞”的游离脂蛋白部分(免疫动物)中存在的胆固醇,比在自身免疫复合物“脂蛋白-抗体”(未免疫动物)中存在的胆固醇,在肝脏组织中更容易氧化为胆汁酸);2)负责从生物体中清除胆固醇(氧化为胆汁酸、随胆汁排泄)的酶和生物系统,在新生动物用富含胆固醇的脂蛋白部分免疫后被激活。

相似文献

1
[Cholesterol metabolism in rabbits with resistance to experimental atherosclerosis acquired by immunological treatment].[经免疫治疗获得实验性动脉粥样硬化抗性的家兔的胆固醇代谢]
Vopr Med Khim. 1977 Nov-Dec(6):803-7.
2
[Nature of the lipoprotein antigen responsible for the development of resistance to experimental atherosclerosis following its use in immunization of newborn rabbits].
Vopr Med Khim. 1978 Jan-Feb;24(1):131-6.
3
[Lipid metabolism in tolerance to experimental atherosclerosis induced by homologous beta-lipoproteins in newborn animals].[新生动物同源β-脂蛋白诱导的实验性动脉粥样硬化耐受性中的脂质代谢]
Vestn Akad Med Nauk SSSR. 1972;27(7):78-85.
4
Increased levels of high-density lipoprotein cholesterol are ineffective in inhibiting the development of immune responses to oxidized low-density lipoprotein and atherosclerosis in transgenic rabbits expressing human apolipoprotein (apo) A-I with severe hypercholesterolaemia.在患有严重高胆固醇血症且表达人载脂蛋白(apo)A-I的转基因兔中,高密度脂蛋白胆固醇水平升高在抑制对氧化型低密度脂蛋白的免疫反应及动脉粥样硬化发展方面无效。
Clin Sci (Lond). 2001 Mar;100(3):343-55.
5
The role of dietary oxidized cholesterol and oxidized fatty acids in the development of atherosclerosis.膳食氧化胆固醇和氧化脂肪酸在动脉粥样硬化发展中的作用。
Mol Nutr Food Res. 2005 Nov;49(11):1075-82. doi: 10.1002/mnfr.200500063.
6
Cholesterol balance in atherosclerosis-susceptible atherosclerosis-resistant pigeons.易患动脉粥样硬化和抗动脉粥样硬化鸽子的胆固醇平衡
Res Commun Chem Pathol Pharmacol. 1975 Jan;10(1):181-4.
7
[The effect of hyperlipoproteinemia induced by the administration of an atherogenic lipoprotein fraction on various indices of lipid metabolism in rabbits].[给予致动脉粥样硬化脂蛋白组分诱导的高脂血症对家兔脂质代谢各项指标的影响]
Vopr Med Khim. 1987 May-Jun;33(3):42-5.
8
[Plasma lipoproteins and aortic collagen fractions in rabbits with different degrees of atherosclerosis].[不同程度动脉粥样硬化兔的血浆脂蛋白与主动脉胶原组分]
Vopr Med Khim. 1979 Jul-Aug;25(4):471-80.
9
Increased binding of LDL and VLDL to apo B,E receptors of hepatic plasma membrane of rats treated with Fibernat.用Fibernat治疗的大鼠肝细胞膜载脂蛋白B、E受体与低密度脂蛋白和极低密度脂蛋白的结合增加。
Eur J Nutr. 2003 Oct;42(5):262-71. doi: 10.1007/s00394-003-0420-8.
10
Development of accelerated atherosclerosis. Concepts derived from cell biology and animal model studies.加速动脉粥样硬化的发展。源自细胞生物学和动物模型研究的概念。
Arch Pathol Lab Med. 1983 Aug;107(8):393-9.

引用本文的文献

1
Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study.脂肪组织来源口服制剂 V-6 Immunitor(V-6)的安全性和疗效试验:开放标签、为期两个月的随访研究结果。
Lipids Health Dis. 2010 Feb 2;9:14. doi: 10.1186/1476-511X-9-14.